A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients

Min Jeong Shin, Young Cho Eun, Yangsoo Jang, Ho Lee Jong, Won Heum Shim, Seung Yun Cho, Se Joong Rim, Seok Min Kang, Jong Won Ha, Young Guk Ko, Sung Soon Kim, Young Park Hyun, Namsik Chung

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: The effect of simvastatin on DNA damage in hypercholesterolemic patients was investigated, and the relationship between the C242T polymorphism of the NADPH oxidase p22phox gene and the antioxidant effects of simvastatin was examined. Methods: Simvastatin (20-40 mg /day) was administered for 8 weeks in 72 hypercholesterolemic patients. DNA damage in lymphocytes was quantified using single-cell gel electrophoresis (COMET assay) by measuring tail DNA (%), tail length (μm) and tail moment (tail length × % tail DNA / 100). Results: Simvastatin significantly reduced DNA damage as expressed by tail DNA (%, p < 0.001), tail length (μm, p < 0.001) and tail moment on the DNA in lymphocytes (p < 0.001) after 8 weeks. The frequencies of the C242T genotypes for CC, TC, and TT were 75.0%, 23.6% and 1.4% in the subjects. In the presence of the 242T allele, there were higher levels of baseline DNA damage and also a greater improvement in the DNA damage after 8 week simvastatin treatment compared with the CC homozygotes. Conclusion: Simvastatin significantly reduced DNA damage of hypercholesterolemic patients. This study showed that simvastatin has a beneficial effect on the improvement of DNA damage in patients with the 242T allele of NADPH oxidase p22phox gene.

Original languageEnglish
Pages (from-to)46-51
Number of pages6
JournalClinica Chimica Acta
Volume360
Issue number1-2
DOIs
Publication statusPublished - 2005 Oct 1

Fingerprint

Simvastatin
NADPH Oxidase
DNA Damage
Alleles
DNA
Lymphocytes
Comet Assay
Homozygote
Genes
Antioxidants
Genotype
Electrophoresis
Polymorphism
Assays
Gels

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Shin, Min Jeong ; Eun, Young Cho ; Jang, Yangsoo ; Jong, Ho Lee ; Shim, Won Heum ; Cho, Seung Yun ; Rim, Se Joong ; Kang, Seok Min ; Ha, Jong Won ; Ko, Young Guk ; Kim, Sung Soon ; Hyun, Young Park ; Chung, Namsik. / A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients. In: Clinica Chimica Acta. 2005 ; Vol. 360, No. 1-2. pp. 46-51.
@article{007e430bb7f744cda0a8b2970745f5b0,
title = "A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients",
abstract = "Background: The effect of simvastatin on DNA damage in hypercholesterolemic patients was investigated, and the relationship between the C242T polymorphism of the NADPH oxidase p22phox gene and the antioxidant effects of simvastatin was examined. Methods: Simvastatin (20-40 mg /day) was administered for 8 weeks in 72 hypercholesterolemic patients. DNA damage in lymphocytes was quantified using single-cell gel electrophoresis (COMET assay) by measuring tail DNA ({\%}), tail length (μm) and tail moment (tail length × {\%} tail DNA / 100). Results: Simvastatin significantly reduced DNA damage as expressed by tail DNA ({\%}, p < 0.001), tail length (μm, p < 0.001) and tail moment on the DNA in lymphocytes (p < 0.001) after 8 weeks. The frequencies of the C242T genotypes for CC, TC, and TT were 75.0{\%}, 23.6{\%} and 1.4{\%} in the subjects. In the presence of the 242T allele, there were higher levels of baseline DNA damage and also a greater improvement in the DNA damage after 8 week simvastatin treatment compared with the CC homozygotes. Conclusion: Simvastatin significantly reduced DNA damage of hypercholesterolemic patients. This study showed that simvastatin has a beneficial effect on the improvement of DNA damage in patients with the 242T allele of NADPH oxidase p22phox gene.",
author = "Shin, {Min Jeong} and Eun, {Young Cho} and Yangsoo Jang and Jong, {Ho Lee} and Shim, {Won Heum} and Cho, {Seung Yun} and Rim, {Se Joong} and Kang, {Seok Min} and Ha, {Jong Won} and Ko, {Young Guk} and Kim, {Sung Soon} and Hyun, {Young Park} and Namsik Chung",
year = "2005",
month = "10",
day = "1",
doi = "10.1016/j.cccn.2005.04.001",
language = "English",
volume = "360",
pages = "46--51",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients. / Shin, Min Jeong; Eun, Young Cho; Jang, Yangsoo; Jong, Ho Lee; Shim, Won Heum; Cho, Seung Yun; Rim, Se Joong; Kang, Seok Min; Ha, Jong Won; Ko, Young Guk; Kim, Sung Soon; Hyun, Young Park; Chung, Namsik.

In: Clinica Chimica Acta, Vol. 360, No. 1-2, 01.10.2005, p. 46-51.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients

AU - Shin, Min Jeong

AU - Eun, Young Cho

AU - Jang, Yangsoo

AU - Jong, Ho Lee

AU - Shim, Won Heum

AU - Cho, Seung Yun

AU - Rim, Se Joong

AU - Kang, Seok Min

AU - Ha, Jong Won

AU - Ko, Young Guk

AU - Kim, Sung Soon

AU - Hyun, Young Park

AU - Chung, Namsik

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Background: The effect of simvastatin on DNA damage in hypercholesterolemic patients was investigated, and the relationship between the C242T polymorphism of the NADPH oxidase p22phox gene and the antioxidant effects of simvastatin was examined. Methods: Simvastatin (20-40 mg /day) was administered for 8 weeks in 72 hypercholesterolemic patients. DNA damage in lymphocytes was quantified using single-cell gel electrophoresis (COMET assay) by measuring tail DNA (%), tail length (μm) and tail moment (tail length × % tail DNA / 100). Results: Simvastatin significantly reduced DNA damage as expressed by tail DNA (%, p < 0.001), tail length (μm, p < 0.001) and tail moment on the DNA in lymphocytes (p < 0.001) after 8 weeks. The frequencies of the C242T genotypes for CC, TC, and TT were 75.0%, 23.6% and 1.4% in the subjects. In the presence of the 242T allele, there were higher levels of baseline DNA damage and also a greater improvement in the DNA damage after 8 week simvastatin treatment compared with the CC homozygotes. Conclusion: Simvastatin significantly reduced DNA damage of hypercholesterolemic patients. This study showed that simvastatin has a beneficial effect on the improvement of DNA damage in patients with the 242T allele of NADPH oxidase p22phox gene.

AB - Background: The effect of simvastatin on DNA damage in hypercholesterolemic patients was investigated, and the relationship between the C242T polymorphism of the NADPH oxidase p22phox gene and the antioxidant effects of simvastatin was examined. Methods: Simvastatin (20-40 mg /day) was administered for 8 weeks in 72 hypercholesterolemic patients. DNA damage in lymphocytes was quantified using single-cell gel electrophoresis (COMET assay) by measuring tail DNA (%), tail length (μm) and tail moment (tail length × % tail DNA / 100). Results: Simvastatin significantly reduced DNA damage as expressed by tail DNA (%, p < 0.001), tail length (μm, p < 0.001) and tail moment on the DNA in lymphocytes (p < 0.001) after 8 weeks. The frequencies of the C242T genotypes for CC, TC, and TT were 75.0%, 23.6% and 1.4% in the subjects. In the presence of the 242T allele, there were higher levels of baseline DNA damage and also a greater improvement in the DNA damage after 8 week simvastatin treatment compared with the CC homozygotes. Conclusion: Simvastatin significantly reduced DNA damage of hypercholesterolemic patients. This study showed that simvastatin has a beneficial effect on the improvement of DNA damage in patients with the 242T allele of NADPH oxidase p22phox gene.

UR - http://www.scopus.com/inward/record.url?scp=24044466782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044466782&partnerID=8YFLogxK

U2 - 10.1016/j.cccn.2005.04.001

DO - 10.1016/j.cccn.2005.04.001

M3 - Article

C2 - 15936011

AN - SCOPUS:24044466782

VL - 360

SP - 46

EP - 51

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -